Xanthomonas maltophilia bacteremia in immunocompromised hematological patients.
Epidemiological, microbiological and clinical characteristics of 14 episodes of Xanthomonas maltophilia bacteremia in 12 seriously immunocompromised hematological patients, admitted to Rigshospitalet in Copenhagen over the 3-year period 1989-91, were evaluated. The results were compared with a randomly selected control group of 25 patients with Escherichia coli bacteremia. Hospital acquired bacteremia was more common among the patients with X. maltophilia bacteremia (p < 0.01). Treatment with broad-spectrum antibiotics before the bacteremic episode was markedly more common among the patients with X. maltophilia bacteremia (p < 0.001). The presence of a central venous catheter and previous treatment with corticosteroids were more frequent in patients with X. maltophilia bacteremia (p < 0.05). The X. maltophilia blood culture isolates were generally resistant to aminoglycosides and most beta-lactams. The mortality rates related to bacteremia caused by X. maltophilia and E. coli were 14% and 20%, respectively.
Victor
M A
MA
Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Arpi
M
M
Bruun
B
B
Jønsson
V
V
Hansen
M M
MM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016470:Bacteremia / Q000150:complications* / Q000453:epidemiology / Q000382:microbiology; D002648:Child; D003428:Cross Infection / Q000453:epidemiology; D004926:Escherichia coli / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000150:complications; D005260:Female; D006088:Gram-Negative Aerobic Bacteria / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000150:complications* / Q000453:epidemiology; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D014974:Xanthomonas / Q000187:drug effects / Q000302:isolation & purification*
D000900:Anti-Bacterial Agents